Skip to main content
logo
Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
2.160
+0.100 (4.85%)
At close: Jul 30, 2025, 4:00 PM
2.170
+0.010 (0.46%)
After-hours: Jul 30, 2025, 5:03 PM EDT

Company Description

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies.

It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.

The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Citius Oncology, Inc.
Citius Oncology logo
CountryUnited States
Founded2021
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
CEOLeonard Mazur

Contact Details

Address:
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
United States
Phone(908) 967-6677

Stock Details

Ticker SymbolCTOR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearOctober - September
Reporting CurrencyUSD
CIK Code0001851484
ISIN NumberUS17331Y1091
SIC Code2834

Key Executives

NamePosition
Leonard L. MazurChairman, Chief Executive Officer and President
Myron Z. HolubiakExecutive Vice Chairman and Secretary
Dr. Myron S. Czuczman M.D.Chief Medical Officer
Jaime BartushakChief Financial Officer and Treasurer

Latest SEC Filings

DateTypeTitle
Jul 25, 2025SCHEDULE 13D/AFiling
Jul 18, 20258-KCurrent Report
Jul 17, 2025424B4Prospectus
Jul 16, 2025EFFECTNotice of Effectiveness
Jul 14, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Jul 14, 2025S-1General form for registration of securities under the Securities Act of 1933
Jun 27, 20258-KCurrent Report
Jun 17, 20258-KCurrent Report
May 14, 202510-QQuarterly Report
May 14, 20258-KCurrent Report
View All SEC Filings